GlaxoSmithKline Files for Approval of Melanoma Drug Combo

GlaxoSmithKline has filed for U.S. approval of a two-drug combination against melanoma earlier than some analysts expected. Britain's biggest pharmaceuticals group said it had submitted the combination of dabrafenib and trametinib to the U.S. FDA based on data from a Phase I/II study. Read more